drugset / Trial / NCT03067688

Clinical Trial of Temisartan/Amlodipine & Rosuvastatin in Subjects With Hypertension and Hyperlipidemia

NCT03067688

Phase 3 Completed 202 enrolled Yuhan Corporation
RandomizedParallel-groupDouble-blindTreatment

Summary

Randomized, double-blind, active-controlled, multicenter phase 3 trial to evaluate efficacy and safety of co-administrated temisartan/amlodipine and rosuvastatin in subjects with hypertension and hyperlipidemia.

Timeline

Start
2017-04-11
Primary completion
2018-03-27
Completion
2018-03-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Amlodipine Other / unclassified 5 mg Oral
Subject Rosuvastatin Small molecule 20 mg Oral
Background Telmisartan Other / unclassified 80 mg Oral